Table 2.
Comparison of symptoms and laboratory test results at presentation between the 2 groups
| Symptom | Control group 1 (n=107) | Case group 2 (n=83) | P value |
|---|---|---|---|
| Symptoms at presentation | |||
| Fever | 63 (60.6) | 48 (57.8) | .765 |
| Cough | 76 (73.1) | 65 (78.3) | .495 |
| Dyspnea | 46 (44.7) | 25 (30.1) | .049 |
| Anosmia or ageusia | 36 (34.6) | 15 (18.1) | .013 |
| Fatigue and myalgia | 70 (67.3) | 26 (31.3) | <.001 |
| URT symptoms (runny nose, blocked nose, sore throat) | 41 (39.4) | 9 (10.8) | <.001 |
| Gastrointestinal symptoms (diarrhea, abdominal pain, nausea, vomiting) | 22 (21.2) | 8 (9.6) | .044 |
| Others (headache, chest discomfort, cutaneous rash) | 44 (42.3) | 10 (12.0) | <.001 |
| Laboratory tests | |||
| Hemoglobin, g/dL | 12.98±1.69 | 11.23±1.32 | <.001 |
| Platelet count, ×109/L | 236.91±123.39 | 228.97±92.55 | .896 |
| WBC count, ×109/L | 6.93±4.55 | 7.49±3.38 | .066 |
| Lymphocyte count, ×109/L | 1.45±0.81 | 1.17±0.51 | .116 |
| Lymphocytopenia | 13 (29.5) | 31 (45.6) | .114 |
| Neutrophil count, ×109/L | 4.74±3.97 | 3.84±3.26 | .876 |
| Prothrombin time activity, % | 97.46±13.55 | 102.40±11.28 | .160 |
| aPTT ratio | 1.05±0.18 | 1.08±0.22 | .131 |
| Abnormal aPTT | 5 (13.5) | 19 (31.1) | .056 |
| Fibrinogen, mg/dL | 513.25±135.07 | 488.56±133.43 | .339 |
| AST, IU/L | 47.97±36.60 | 35.49±23.85 | .004 |
| ALT, IU/L | 45.50±40.44 | 27.84±30.51 | <.001 |
| CRP, mg/dL | 73.50±78.23 | 34.17±37.10 | .014 |
| Creatinine, mg/L | 0.69±0.16 | 0.61±0.41 | <.001 |
| LDH, IU/L | 320.08±119.48 | 246.00±4.58 | .396 |
| D-dimers, ng/mL | 781.50±508.58 | 1112.00±388.69 | .046 |
Data are presented as number (percentage) and mean±standard deviation.
ALT, alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; CRP, C-reactive protein; LDH, lactate dehydrogenase; URT, upper respiratory tract; WBC, white blood cell.
Badr. Coronavirus disease 2019 in pregnancy. Am J Obstet Gynecol 2020.